Bruker Corporation (BRKR) - Total Liabilities
Based on the latest financial reports, Bruker Corporation (BRKR) has total liabilities worth $3.73 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bruker Corporation - Total Liabilities Trend (1998–2025)
This chart illustrates how Bruker Corporation's total liabilities have evolved over time, based on quarterly financial data. See Bruker Corporation short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Bruker Corporation Competitors by Total Liabilities
The table below lists competitors of Bruker Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
USA | $342.12 Million |
|
Inner Mongolia Yitai Coal Co Ltd
SHG:900948
|
China | $39.00 Billion |
|
Bilibili Inc
NASDAQ:BILI
|
USA | $25.64 Billion |
|
Gerdau S.A
MX:GGBN
|
Mexico | MX$28.08 Billion |
|
Capital Securities Corp. Ltd.
SHG:601136
|
China | CN¥40.50 Billion |
|
Kuala Lumpur Kepong Bhd
KLSE:2445
|
Malaysia | RM16.25 Billion |
|
BILIBILI INC. DL -0001
F:71BB
|
Germany | €25.62 Billion |
|
MEIJI HLD.UN.ADR 1/4 O.N.
F:3M00
|
Germany | €440.05 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Bruker Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BRKR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bruker Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bruker Corporation (1998–2025)
The table below shows the annual total liabilities of Bruker Corporation from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.73 Billion | -6.52% |
| 2024-12-31 | $3.99 Billion | +40.71% |
| 2023-12-31 | $2.84 Billion | +14.38% |
| 2022-12-31 | $2.48 Billion | -3.32% |
| 2021-12-31 | $2.57 Billion | +23.64% |
| 2020-12-31 | $2.07 Billion | +13.17% |
| 2019-12-31 | $1.83 Billion | +49.84% |
| 2018-12-31 | $1.22 Billion | +0.70% |
| 2017-12-31 | $1.22 Billion | +8.50% |
| 2016-12-31 | $1.12 Billion | +12.20% |
| 2015-12-31 | $998.00 Million | -8.70% |
| 2014-12-31 | $1.09 Billion | -3.95% |
| 2013-12-31 | $1.14 Billion | -0.76% |
| 2012-12-31 | $1.15 Billion | +5.64% |
| 2011-12-31 | $1.09 Billion | +6.18% |
| 2010-12-31 | $1.02 Billion | +35.74% |
| 2009-12-31 | $753.20 Million | -6.27% |
| 2008-12-31 | $803.60 Million | +173.32% |
| 2007-12-31 | $294.02 Million | +21.75% |
| 2006-12-31 | $241.48 Million | +57.98% |
| 2005-12-31 | $152.85 Million | -0.80% |
| 2004-12-31 | $154.08 Million | +3.77% |
| 2003-12-31 | $148.48 Million | +93.53% |
| 2002-12-31 | $76.72 Million | +24.70% |
| 2001-12-31 | $61.53 Million | +1.90% |
| 2000-12-31 | $60.38 Million | +5.47% |
| 1999-12-31 | $57.25 Million | +7.01% |
| 1998-12-31 | $53.50 Million | -- |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, ser… Read more